| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Wellness publication |
| Population | Men |
| Source | The European |
| URL | the-european.eu/?p=57490 (opens in a new tab) |
Specific Claim Evaluated
Testosterone declines by about 1% a year on average, testosterone can suppress sperm production and men may receive unnecessary prescriptions after online blood tests; lifestyle factors should be addressed before treatment.
Primary Research Supporting or Contradicting the Claim
Cohort data show an age-related decline of about 1% per year (Travison et al., 2007), and guidelines require symptoms and repeated morning testing before diagnosis (Bhasin et al., 2018).
Corrected Evidence-Based Interpretation
The article is correct. Testosterone therapy has no demonstrated benefit for work performance in men without hypogonadism.
Rationale for Grade
The article frames testosterone as a treatment for deficiency, cautions against self-diagnosis and states fertility and prostate risks accurately. It does not claim a performance benefit in men with normal testosterone.
References
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID
Supporting excerpt: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs" - Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196-202. PMID
Supporting excerpt: "a substantial, and as yet unrecognized, age-independent population-level decrease in T"